Ivermectina Difa

Ivermectin, the active ingredient in Ivermectina Difa, is an antiparasitic presented as an oral formulation for systemic use. It treats a range of parasitic infections such as onchocerciasis, strongyloidiasis, scabies, pediculosis and other helminthic diseases in adults and children when prescribed by a qualified health professional.

GNH USA supplies Ivermectina Difa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectina Difa belongs to the antiparasitic drug class and is used to treat infections caused by nematodes and ectoparasites. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal larvae and prevents chronic infection. - Scabies: eliminates Sarcoptes scabiei mites, relieving skin lesions. - Pediculosis: kills lice and nits, controlling infestation. - Other helminth infections: broad‑spectrum activity against various intestinal worms.

Ivermectina Difa may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring shortly after dosing. - Dizziness: transient feeling of light‑headedness. - Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects: - Severe skin rash: including Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or jaundice. - Visual disturbances: blurred vision or optic neuritis. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before prescribing Ivermectina Difa, clinicians should consider several safety aspects. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown safety; assess potential infant exposure. - Renal or hepatic impairment: use with caution and monitor function. - Drug interactions: review concomitant medications for potential interactions. - Pediatric use: caution in children weighing less than 15 kg. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Ivermectina Difa can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: may increase anticoagulant effect and bleeding risk. - Carbamazepine: can reduce ivermectin plasma concentrations. - Macrolide antibiotics (e.g., erythromycin): may heighten neurotoxicity. - P‑glycoprotein inhibitors (e.g., verapamil): may raise ivermectin levels.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase ivermectin exposure. - Antiretrovirals (e.g., ritonavir): can alter metabolism and plasma levels. - Diuretics: monitor blood pressure and electrolytes during co‑administration.